Clinical Trial Update: Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/Phase 2 study evaluated the feasibility and safety of combining carboplatin-based chemotherapy (carboplatin with Caelyx or with doxorubic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Caelyx (liposomal doxorubicin)
• Doxorubicin (doxorubicin)
• PEG Intron (pegylated interferon alfa-2b)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Recurrent Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED